Dendreon Corp fka DNDNQ

[rancherho]

More on hmab / GM-CSF secreting GVAX irradiated metastatic cancer cell lines. Anyone interested in reading the full article can access the link to Springer at Pubmed with the following link. The cost is $32. For anyone with some knowledge of the science, this is an absolutely creative and fascinating study. When, not if, the technology is brought forward into human trials and shows any similar success, it has the potential to become the dominant method of cancer immunotherapy since it combines the sensitivity, specificity and power of combining T cell and B cell antibody based immunotherapy in doses effective in the tumor microenvironment without higher systemic levels of antibodies necessary to break tolerance. The methodology also appears adaptible to causing similar expression in vivo of other useful anti-cancer hmabs. It also appears scalable in an allogenic vaccine, eliminating the enormous expenses of producing the hmabs ex vivo. IMO, this is truly world class science.
http://www.ncbi.nlm.nih.gov/sites/entrez